281 related articles for article (PubMed ID: 20600570)
21. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.
Dembek ZF; Smith LA; Rusnak JM
Disaster Med Public Health Prep; 2007 Nov; 1(2):122-34. PubMed ID: 18388640
[TBL] [Abstract][Full Text] [Related]
22. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine.
Yu YZ; Sun ZW; Li N; Wang S; Wang RL; Yu WY
Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):261-6. PubMed ID: 18932057
[TBL] [Abstract][Full Text] [Related]
23. Anti-immunoglobulin responses to IgG, F(ab')2, and Fab botulinum antitoxins in mice.
Mayers CN; Veall S; Bedford RJ; Holley JL
Immunopharmacol Immunotoxicol; 2003 Aug; 25(3):397-408. PubMed ID: 19180802
[TBL] [Abstract][Full Text] [Related]
24. Development of vaccines for prevention of botulism.
Byrne MP; Smith LA
Biochimie; 2000; 82(9-10):955-66. PubMed ID: 11086225
[TBL] [Abstract][Full Text] [Related]
25. Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function.
Tremblay JM; Vazquez-Cintron E; Lam KH; Mukherjee J; Bedenice D; Ondeck CA; Conroy MT; Bodt SML; Winner BM; Webb RP; Ichtchenko K; Jin R; McNutt PM; Shoemaker CB
Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32987745
[TBL] [Abstract][Full Text] [Related]
26. Botulinum neurotoxin vaccines: past, present, and future.
Smith LA; Rusnak JM
Crit Rev Immunol; 2007; 27(4):303-18. PubMed ID: 18197811
[TBL] [Abstract][Full Text] [Related]
27. A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model.
Snow DM; Cobb RR; Martinez J; Finger-Baker I; Collins L; Terpening S; Syar ES; Niemuth N; Kobs D; Barnewall R; Farr-Jones S; Marks JD; Tomic MT
Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33466411
[TBL] [Abstract][Full Text] [Related]
28. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.
Fan Y; Garcia-Rodriguez C; Lou J; Wen W; Conrad F; Zhai W; Smith TJ; Smith LA; Marks JD
PLoS One; 2017; 12(3):e0174187. PubMed ID: 28323873
[TBL] [Abstract][Full Text] [Related]
29. Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin.
Fagan RP; Neil KP; Sasich R; Luquez C; Asaad H; Maslanka S; Khalil W
Clin Infect Dis; 2011 Nov; 53(9):e125-8. PubMed ID: 21896700
[TBL] [Abstract][Full Text] [Related]
30. Immunologic and Protective Properties of Subunit- vs. Whole Toxoid-Derived Anti-Botulinum Equine Antitoxin.
Ben David A; Barnea A; Torgeman A; Diamant E; Dor E; Schwartz A; Rosen O; Caspi N; Saraf M; Lerer E; Adar Y; Lupo E; Toister E; Zichel R
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146601
[TBL] [Abstract][Full Text] [Related]
31. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B.
Yang GH; Kim KS; Kim HW; Jeong ST; Huh GH; Kim JC; Jung HH
Toxicon; 2004 Jul; 44(1):19-25. PubMed ID: 15225558
[TBL] [Abstract][Full Text] [Related]
32. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
[TBL] [Abstract][Full Text] [Related]
33. [Effects of immunoglobulin on murine myocarditis caused by influenza A virus: experimental study].
Kishimoto C; Hiraoka Y; Takada H; Kurokawa M; Ochiai H
J Cardiol; 2005 Jun; 45(6):247-55. PubMed ID: 15991608
[TBL] [Abstract][Full Text] [Related]
34. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains.
Dolimbek GS; Dolimbek BZ; Aoki KR; Atassi MZ
Immunol Invest; 2005; 34(2):119-42. PubMed ID: 15921155
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
Khouri JM; Motter RN; Arnon SS
Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
[TBL] [Abstract][Full Text] [Related]
36. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
Yu YZ; Liu S; Ma Y; Gong ZW; Wang S; Sun ZW
Hum Vaccin Immunother; 2014; 10(7):1874-9. PubMed ID: 25424795
[TBL] [Abstract][Full Text] [Related]
37. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.
Mukherjee J; Tremblay JM; Leysath CE; Ofori K; Baldwin K; Feng X; Bedenice D; Webb RP; Wright PM; Smith LA; Tzipori S; Shoemaker CB
PLoS One; 2012; 7(1):e29941. PubMed ID: 22238680
[TBL] [Abstract][Full Text] [Related]
38. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library.
Yu R; Wang S; Yu YZ; Du WS; Yang F; Yu WY; Sun ZW
J Biomol Screen; 2009 Sep; 14(8):991-8. PubMed ID: 19726786
[TBL] [Abstract][Full Text] [Related]
39. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
Dunn DL; Mach PA; Condie RM; Cerra FB
Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters.
Jathoul AP; Holley JL; Garmory HS
Vaccine; 2004 Sep; 22(29-30):3942-6. PubMed ID: 15364442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
